How to access Elrexfio from Saudi Arabia, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi Arabia patient with heavily pre-treated relapsed or refractory multiple myeloma, typically with four or more prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal, may be evaluated by their treating haematologist for Elrexfio (elranatamab). Elrexfio is FDA-approved, developed by Pfizer, and is a subcutaneous BCMAxCD3 bispecific T-cell engager for multiple myeloma. In Saudi Arabia, Elrexfio is not yet broadly registered for routine hospital pharmacy dispensing, which is why your haematologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Elrexfio is a humanised bispecific antibody binding BCMA on myeloma cells and CD3 on T cells. Administration is subcutaneous on a step-up schedule (12 mg then 32 mg on a pre-maintenance cadence) followed by 76 mg weekly, with less-frequent dosing considered after sustained response. The step-up phase requires inpatient monitoring for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) at a facility capable of tocilizumab administration and intensive support. Eligibility anchors to prior-line history, performance status, cytopenia baseline, and infection-risk profile. Your haematologist will identify the administering tertiary centre and plan hypogammaglobulinaemia-related supportive care.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Is Elrexfio legally importable into Saudi Arabia?
Yes, via the Saudi Food and Drug Authority (SFDA) named-patient import framework. The named-patient mechanism permits a Saudi Arabia-licensed physician at a qualified haematology centre to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available at that centre, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.
For Elrexfio specifically, the application emphasises the centre's capability to manage CRS/ICANS during step-up dosing.
How the pathway works, step by step
- Consultation with your treating haematologist. Prior-line documentation, performance status, cytopenia and infection baseline, centre nomination.
- Administering-centre identification. A qualified Saudi Arabia tertiary haematology unit with CRS/ICANS monitoring capability is nominated; step-up beds are booked.
- SFDA named-patient application. Your physician files the dossier including clinical rationale, patient reference, centre capability attestation, and dosing plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Elrexfio from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Elrexfio ships with validated temperature control to the administering hospital pharmacy.
- Step-up admission and ongoing therapy. The tertiary centre admits for step-up dosing, manages CRS/ICANS prophylaxis, transitions to weekly outpatient maintenance.
What documentation your physician needs
- Clinical rationale letter confirming diagnosis, prior-line sequence (≥ 4 prior lines with PI / IMiD / anti-CD38 exposure), and Elrexfio as the indicated therapy
- Verification of the treating physician's Saudi Arabia licence (SFDA / DoH / DHA as applicable)
- Identification of the administering tertiary centre with CRS/ICANS monitoring attestation
- Patient identifier (anonymised reference where possible)
- Step-up and maintenance dosing plan with supportive-care protocol
Reserve Meds provides a documentation kit that bundles the SFDA templates reviewers expect to see for BCMA-directed bispecific named-patient files.
Costs and timing
Elrexfio's US cash-pay drug-only reference cost for the 76 mg weekly maintenance is approximately USD 41,000-47,000 per month in an indicative 2026 drug-only range (delivered quote issued at intake); the step-up month sits at a lower dose level. Inpatient step-up hospitalisation is a separate local cost handled by the administering hospital. International logistics, SFDA documentation handling, cold-chain shipment, and concierge coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake. Indicative range.
Indicative timing for first-dose step-up admission after cohort intake opens is 7-14 days from the moment a complete SFDA application is submitted.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: Saudi Arabia myeloma patients travel from across the kingdom to tertiary haematology centres in Riyadh and Jeddah. Our coordination includes accommodation logistics for the step-up inpatient phase and family-caregiver support throughout.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and SFDA review, keyed to the BCMA-bispecific rationale.
- Logistics. Validated cold-chain shipment to the nominated tertiary centre.
- Concierge case lead. A named point of contact for your family and your haematology team through step-up and maintenance cadence.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and the administering centre.
Frequently asked
How does Elrexfio compare with Tecvayli? Both are BCMAxCD3 bispecifics with similar mechanism and similar step-up dosing schedules. They differ slightly in dosing cadence, supportive-care protocol, and cross-trial response profiles. Your haematologist will select based on the clinical picture.
Where will the step-up admission happen? At a Saudi Arabia tertiary haematology centre with CRS/ICANS experience, your physician nominates the site.
What is the infection risk? BCMA bispecifics are associated with hypogammaglobulinaemia and opportunistic infection risk; IVIG supplementation and antimicrobial prophylaxis are standard. Your team will manage.
Will insurance cover this? Cash-pay is the default for named-patient imports. Some Saudi Arabia private insurers consider case-by-case reimbursement; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-04-23.
Regulatory status of Elrexfio in Saudi Arabia, 2026
Elrexfio (elranatamab-bcmm) is not currently held on the locally registered medicines list of the Saudi Food and Drug Authority (SFDA). The product is approved by the US Food and Drug Administration per the labelled indication of relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).
Because Elrexfio is not on the SFDA locally registered list, access for a Saudi Arabia-based patient runs through the named-patient and personal-import framework that the SFDA maintains for reference-authority-approved medicines that are not held locally. The official SFDA portal is at www.sfda.gov.sa/en. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.
The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into Saudi Arabia; see Block 2 below for the operational shape on that case type.
Tertiary centers and clinical coordination in Saudi Arabia
The Saudi Arabia tertiary referral network for a Elrexfio case is concentrated at King Faisal Specialist Hospital and Research Centre (KFSHRC), King Abdulaziz Medical City (KAMC), and King Fahad Medical City (KFMC). These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into Saudi Arabia. The tertiary Saudi Arabia centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the Saudi Arabia tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.
For oral kinase inhibitors and antibody therapies that can be administered in Saudi Arabia once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule.
Saudi Arabia pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once your treating physician's documentation is in. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only range for Elrexfio sits at approximately USD 41,000 to USD 46,000 per 28-day cycle of BCMA-directed bispecific antibody at standard maintenance dosing (US wholesale acquisition cost). In SAR terms at the 2026 reference rate of 1 USD = 3.750 SAR, that translates to a drug-only band of approximately SAR 153,750 to SAR 172,500.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable (for cellular and gene therapies, the facility cost commonly equals or exceeds the product cost), Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost in 2026 commonly lands at 1.5x to 2.5x the drug-only band once US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation are added in.
Payer posture in Saudi Arabia is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (CCHI essential drug list at https://www.cchi.gov.sa) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Elrexfio case in Saudi Arabia are: (1) Regulatory documentation complexity. The SFDA named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format SFDA reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Elrexfio from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating Saudi Arabia physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Elrexfio: the labelled indication is relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The relevant clinical-practice guideline body is NCCN multiple myeloma guidelines at www.nccn.org. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Elrexfio in Saudi Arabia, 2026
The Saudi Food and Drug Authority (SFDA) portal at www.sfda.gov.sa/en has not posted a Elrexfio-specific listing on the publicly searchable locally registered medicines list at www.sfda.gov.sa/en/drugs-list as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Elrexfio-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody (see the current label at accessdata.fda.gov). Pfizer continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The NCCN multiple myeloma guidelines guidance at www.nccn.org remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.